AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $376.31 billion. The enterprise value is $440.18 billion.
Important Dates
The last earnings date was Wednesday, April 29, 2026, before market open.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | Apr 15, 2026 |
Share Statistics
AbbVie has 1.77 billion shares outstanding. The number of shares has increased by 0.04% in one year.
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 75.94% |
| Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 106.25 and the forward PE ratio is 14.45. AbbVie's PEG ratio is 0.94.
| PE Ratio | 106.25 |
| Forward PE | 14.45 |
| PS Ratio | 6.00 |
| Forward PS | 5.44 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.85 |
| P/OCF Ratio | 17.75 |
| PEG Ratio | 0.94 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 14.71, with an EV/FCF ratio of 22.03.
| EV / Earnings | 122.44 |
| EV / Sales | 7.01 |
| EV / EBITDA | 14.71 |
| EV / EBIT | 20.12 |
| EV / FCF | 22.03 |
Financial Position
The company has a current ratio of 0.80
| Current Ratio | 0.80 |
| Quick Ratio | 0.52 |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.41 |
| Debt / FCF | 3.65 |
| Interest Coverage | 7.52 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 10.03% |
| Return on Invested Capital (ROIC) | 22.83% |
| Return on Capital Employed (ROCE) | 23.19% |
| Weighted Average Cost of Capital (WACC) | 5.36% |
| Revenue Per Employee | $1.10M |
| Profits Per Employee | $63,070 |
| Employee Count | 57,000 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 3.67 |
Taxes
In the past 12 months, AbbVie has paid $2.33 billion in taxes.
| Income Tax | 2.33B |
| Effective Tax Rate | 39.06% |
Stock Price Statistics
The stock price has increased by +16.68% in the last 52 weeks. The beta is 0.30, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +16.68% |
| 50-Day Moving Average | 208.20 |
| 200-Day Moving Average | 219.31 |
| Relative Strength Index (RSI) | 57.68 |
| Average Volume (20 Days) | 5,823,472 |
Short Selling Information
The latest short interest is 20.91 million, so 1.18% of the outstanding shares have been sold short.
| Short Interest | 20.91M |
| Short Previous Month | 20.13M |
| Short % of Shares Out | 1.18% |
| Short % of Float | 1.19% |
| Short Ratio (days to cover) | 3.02 |
Income Statement
In the last 12 months, AbbVie had revenue of $62.82 billion and earned $3.60 billion in profits. Earnings per share was $2.03.
| Revenue | 62.82B |
| Gross Profit | 45.25B |
| Operating Income | 21.88B |
| Pretax Income | 5.98B |
| Net Income | 3.60B |
| EBITDA | 29.92B |
| EBIT | 21.88B |
| Earnings Per Share (EPS) | $2.03 |
Full Income StatementBalance Sheet
The company has $9.39 billion in cash and $72.91 billion in debt, with a net cash position of -$63.52 billion or -$35.95 per share.
| Cash & Cash Equivalents | 9.39B |
| Total Debt | 72.91B |
| Net Cash | -63.52B |
| Net Cash Per Share | -$35.95 |
| Equity (Book Value) | -6.61B |
| Book Value Per Share | -3.77 |
| Working Capital | -8.57B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $21.22 billion and capital expenditures -$1.24 billion, giving a free cash flow of $19.98 billion.
| Operating Cash Flow | 21.22B |
| Capital Expenditures | -1.24B |
| Depreciation & Amortization | 8.04B |
| Net Borrowing | 2.63B |
| Free Cash Flow | 19.98B |
| FCF Per Share | $11.31 |
Full Cash Flow StatementMargins
Gross margin is 72.03%, with operating and profit margins of 34.83% and 5.79%.
| Gross Margin | 72.03% |
| Operating Margin | 34.83% |
| Pretax Margin | 9.51% |
| Profit Margin | 5.79% |
| EBITDA Margin | 47.62% |
| EBIT Margin | 34.83% |
| FCF Margin | 31.81% |
Dividends & Yields
This stock pays an annual dividend of $6.92, which amounts to a dividend yield of 3.25%.
| Dividend Per Share | $6.92 |
| Dividend Yield | 3.25% |
| Dividend Growth (YoY) | 5.64% |
| Years of Dividend Growth | 54 |
| Payout Ratio | 332.01% |
| Buyback Yield | -0.04% |
| Shareholder Yield | 3.20% |
| Earnings Yield | 0.95% |
| FCF Yield | 5.30% |
Dividend DetailsAnalyst Forecast
The average price target for AbbVie is $252.90, which is 18.74% higher than the current price. The consensus rating is "Buy".
| Price Target | $252.90 |
| Price Target Difference | 18.74% |
| Analyst Consensus | Buy |
| Analyst Count | 32 |
| Revenue Growth Forecast (5Y) | 5.05% |
| EPS Growth Forecast (5Y) | 31.91% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 2.29 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.29 |
| Piotroski F-Score | 8 |
